Surgery For Insulinoma Research Articles

A case of insulinoma confused with dumping syndrome after total gastrectomy

We present the case of a 70-year-old female patient with persistent hypoglycemia after total gastrectomy due to gastrointestinal stromal tumors. She was thought to have late dumping syndrome but was diagnosed with insulinoma after further examination. Dumping syndrome is mainly seen after stomach or esophageal surgery. It is divided into early dumping and late dumping syndrome. Late dumping syndrome is initially manifested by an exaggerated insulin response and reactive hypoglycemia after glucagon-like peptide-1 release. Diagnosis is based on clinical findings. Treatment mainly consists of reducing carbohydrate intake and not ingesting solid and liquid foods together. In cases where diet alone is not sufficient, acarbose, an α-glucosidase inhibitor that slows the digestion of carbohydrates, may be beneficial for late dumping. Octreotide can be used in resistant cases. However, the diagnosis of insulinoma, which leads to a similar clinical presentation in resistant dumping cases, should be kept in mind. Our patient who showed clinical signs of dumping syndrome after gastrectomy, and treatment-resistant hypoglycemia was diagnosed with insulinoma on the basis of further investigations. The patient’s symptoms resolved after surgery for insulinoma.

Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients.

This study was aimed to investigate the role and relevance of endoscopic ultrasound-guided fine-needle aspiration biopsy in the diagnostic work-up of insulinomas. We have analysed the frequency, clinical indications, success rate (obtaining diagnostic tissue), diagnostic accuracy (in comparison to the pathological diagnosis after surgery), complications, and tolerability of endoscopic ultrasound-guided fine-needle aspiration biopsy and the localization and size of the lesions in 47 consecutive patients (29 females, 18 males; 46 ± 15 years) who had surgery for insulinoma following fasting test and were explored by single investigator EUS 1994-2015. Endoscopic ultrasound-guided fine-needle aspiration biopsy was performed in 21 % (10/47) of the patients. The clinical indications for endoscopic ultrasound-guided fine-needle aspiration biopsy were non-conclusive result of fasting test (n = 7), missing toxicology (n = 2), suspected malignancy at EUS (n = 1), suspicious extra-pancreatic localization of the lesion (n = 1). The diagnostic success rate of the procedure was 80 % (8/10 cases), the diagnostic accuracy of the fine-needle aspiration biopsy 70 % (7/10 cases). The lesions undergoing endoscopic ultrasound-guided fine-needle aspiration biopsy were localized in the cauda (n = 5), corpus (n = 2), caput/processus uncinatus (n = 3), the diameter of the tumors was 21 ± 18 (10-70) mm. Only one accidental vascular puncture without any clinical complication occurred and all patients tolerated the procedure well. In the majority of cases, positive fasting test, negative toxicology, and detection of a typical pancreatic lesion at endoscopic ultrasound is sufficient for the diagnosis of insulinoma and the definition of the appropriate surgical strategy. Based on our data, we suggest including endoscopic ultrasound-guided fine-needle aspiration biopsy in the diagnostic work-up of organic hyperinsulinism in selected patients with inconclusive or uncertain diagnosis before surgery.

Prospective Evaluation of Biweekly Streptozotocin in 19 Dogs with Insulinoma

Administration of streptozotocin (STZ) at a 21-day interval has been described in dogs with stage II and III insulinoma. Myelosuppression was not observed, suggesting the possibility of increasing dose intensity by decreasing the interval between doses. To describe the tolerability of a biweekly STZ protocol. A secondary objective was to describe the outcome of dogs treated with this protocol. Nineteen dogs with residual local, metastatic, or recurrent insulinoma. After surgery for insulinoma, or at the time of recurrence, dogs were treated with a previously described STZ and saline diuresis protocol. Treatments were administered every 14 days. All dogs received antiemetic treatment. Adverse events (AEs) were recorded and graded. Outcome endpoints assessed were progression-free survival (PFS) and survival. None of the dogs experienced neutropenia or thrombocytopenia. Mild to moderate gastrointestinal toxicity was the most common AE. Diabetes mellitus was observed in 8 dogs and, in 6, resulted in euthanasia or death. Two dogs developed nephrotoxicity manifested as Fanconi syndrome in 1 and nephrogenic diabetes insipidus in the other. Six dogs developed increased alanine amino transferase activity. Hypoglycemia at the end of the STZ infusion, resulted in collapse in 1 dog and a generalized seizure in another. The median overall PFS and survival time were 196 and 308 days, respectively. Streptozotocin can be safely administered to dogs with insulinoma, but serious AEs are possible. Additional investigation is required to better define the role of STZ in managing dogs with insulinoma.

Nursing cooperation in the laparoscopic surgery for insulinoma

Objective To study nursing experience of laparoscopic insulinoma resections.Methods 50 operation processes of laparoscopic insulinoma resection were summarized. Results We got satisfied effects through perioperation nursing management. All operations were smooth and no accidence occurred. Conclusions Laparoscopic resection of pancreatic insulinoma has less damage to patients.Enhancing perioperation management to patients, paying attention to monitor and adjusting blood glucose and preventing occurrence of hypoglycemia coma should be done to ensure operation being carried out safely and smoothly. Key words: Insulin-Secreting cells; Laparoscopy; Nursing; Isulinoma

Surgery for Primary Pancreatic Neuroendocrine Tumors

Currently, surgery for insulinoma is curative in nearly every patient, even those with MEN1, and fu-ture direction seems to be to make it more cosmeti-cally acceptable and less morbid by trying to accomplish the same procedure laparoscopically. Surgery for gastrinoma and nonfunctional NE tu-mors is curative in approximately 50% of patients. Duodenotomy is indicated during surgery for gastri-noma, because it increases tumor detection and cure rate. Patients with MEN1 with gastrinoma remain a challenge. With our current approach in these pa-tients, the cure rate is low, but the long-term survival remains excellent. The role of routine pancreaticoduodenectomy for sporadic and MEN1 NE tumors is currently unclear. It may increase cure rate, but it may also increase morbidity in pa-tients with a low, long-term tumor death rate.

Reoperative insulinomas, 1927 to 1992: an institutional experience.

Between 1927 and 1992, 313 patients have undergone surgery for insulinoma(s) at our institution, 12% of which were reoperations. We retrospectively reviewed all cases (n = 39) of reoperative surgery for persistent hyperinsulinism to identify changing patterns in surgical approach, morbidity, and outcome and to evaluate the influence of preoperative and intraoperative localization studies. The diagnosis of endogenous hyperinsulinism has evolved from satisfying Whipple's triad to documenting concomitant hypoglycemia and endogenous hyperinsulinemia. Thirty-nine patients were divided into two groups for comparison: those treated before localization studies were available (1927 to 1967) (n = 17) and those treated since that time (n = 22). Initial operations were also compared with reoperations among these 39 patients. There were 26 women and 13 men (mean age, 42 years). There was at least one positive preoperative localization study in 16 of 22 patients (73%). Intraoperative ultrasonogram and careful palpation successfully identified 10 of 11 tumors in the reoperative setting. Blind or completion pancreatectomies were common before 1967 (10 of 17 patients). Since 1967, 14 of 22 patients have undergone enucleation of their primary tumor. Operative morbidity increased from 21% to 58% with reoperation but decreased from 65% to 29% (p = 0.026) when comparing the preangiography to the postangiography eras. The development of iatrogenic diabetes mellitus occurred in 13 patients (33%) after reoperation. Forty-one percent had diabetes before 1967 and 27% since that time (p = not significant). Thirty-four of 36 patients (94%) without malignant tumors were cured by reoperation. There was one operative death. Survival for patients who underwent completion or total pancreatectomy was significantly reduced (p = 0.003). Reoperations for persistent hyperinsulinism can be highly successful in experienced hands. These reoperations, however, are associated with increased morbidity and iatrogenic diabetes. With experience and the use of selected localization studies, first-time failures can be avoided in most cases thus reducing the need for reoperations and its inherent sequelae.

Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma.

We have investigated the hypothesis that insulin is a causal and independent risk factor for blood pressure elevation in humans by comparing pre- and post-operative blood pressure values of 34 consecutive patients with histologically-confirmed diagnosis of insulinoma and 34 age- and sex-matched control patients. In patients with insulinoma hypoglycaemic symptoms were present for 18 (9-36) months. (Values are given as median and 95% confidence interval or mean and SD). After removal of insulinoma fasting plasma insulin levels decreased from 22 (16-28) mU/l to 11 (6-20) mU/l (p less than 0.003) and minimal fasting plasma glucose concentrations increased from 2.5 (2.0-3.0) to 4.4 (4.2-5.7) mmol/l (p less than 0.002) while blood pressure values remained unchanged. Body mass index before operation was comparable between the groups: 25.5 (5.4) kg/m2 in insulinoma patients and 24.8 (4.7) kg/m2 in control subjects. Pre-operative and post-operative blood pressure values did not differ between the groups, being (systolic/diastolic) 133 (18)/82 (9) mm Hg in insulinoma patients and 128 (15)/78 (10) mm Hg in control subjects before and 129 (19)/80 (10) mm Hg and 125 (11)/76 (7) after surgery. Chronic hyperinsulinaemia in patients with insulinoma is not associated with a detectable elevation of blood pressure values. Correction of hyperinsulinaemia after surgery for insulinoma does not result in blood pressure changes. These results argue against the hypothesis that insulin is an independent causal factor in the development of essential hypertension in humans.

Diagnostic monitoring of plasma levels of glucose and insulin during surgery for insulinoma

With serial measurement of blood sugar levels during surgery in three patients with solitary insulinoma, we confirmed the location, then later, the complete elimination of the insulin-secreting tumor. Following vigorous massage of the tumor, blood sugar levels decreased while the levels progressively increased within 20 min following removal of the tumor. Subsequent measurement of simultaneous plasma insulin levels provided further confirmation. Plasma levels of insulin increased in accordance with massage of the tumor. Prior to removal of the tumor, the levels progressively decreased to less than the preoperative levels. For success in detecting slight changes in blood sugar levels secondary to increase or decrease of insulin secretion during surgery for insulinoma, (1) controlled infusion of glucose to keep blood sugar levels around 80 mg/dl and (2) frequent rapid determination of blood sugar levels are considered to be important.